Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy

Area of Science:

• Pediatric Oncology
• Immunotherapy
• Cellular Therapy

Background:

• High-risk pediatric solid tumors (metastatic, relapsed) have poor prognoses despite current treatments.
• Adoptive cellular therapy (ACT) shows efficacy in adult cancers, presenting an opportunity for pediatric application.
• Pediatric immunotherapy has yielded modest results, primarily with antibody-based and CAR T-cell therapies for lymphoid cancers.

Purpose of the Study:

• To review ACT strategies for pediatric solid tumors, excluding CAR T-cell therapy.
• To highlight ongoing clinical trials and promising preclinical data in ACT for pediatric malignancies.
• To advance understanding of cellular and molecular mechanisms for improved ACT efficacy.

Main Methods:

• Review of completed and ongoing clinical trials in ACT for pediatric solid tumors.
• Analysis of preclinical data focusing on tumor-infiltrating lymphocytes (TILs).
• Exploration of ACT mechanisms beyond chimeric antigen receptor T-cell therapy.

Main Results:

• ACT strategies beyond CAR T-cell therapy are being investigated for pediatric solid tumors.
• Tumor-infiltrating lymphocytes show promise in preclinical studies for enhancing ACT efficacy.
• Understanding ACT mechanisms is crucial for developing better pediatric cancer treatments.

Conclusions:

• There is a significant need for novel therapeutic strategies for high-risk pediatric solid tumors.
• ACT, particularly TILs, offers a promising avenue for improving outcomes in pediatric cancer.
• Further research into ACT mechanisms can lead to more effective treatments for children and adolescents.